Vanguard Group Inc Lyra Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,779,263 shares of LYRA stock, worth $338,059. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,779,263

Previous 1,730,915 2.79%

Holding current value

$338,059

Previous $484,000 4.55%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.24 - $0.34 $11,603 - $16,438	48,348 Added 2.79%	1,779,263 $462,000
Q2 2024 Aug 13, 2024	BUY	$0.26 - $6.25 $64,852 - $1.56 Million	249,434 Added 16.84%	1,730,915 $484,000
Q1 2024 May 10, 2024	BUY	$4.55 - $6.53 $1.87 Million - $2.68 Million	410,021 Added 38.27%	1,481,481 $9.21 Million
Q4 2023 Feb 14, 2024	BUY	$2.82 - $5.24 $584,100 - $1.09 Million	207,128 Added 23.96%	1,071,460 $5.61 Million
Q3 2023 Nov 14, 2023	BUY	$2.95 - $4.8 $216,518 - $352,300	73,396 Added 9.28%	864,332 $3.38 Million
Q4 2022 Feb 10, 2023	BUY	$2.44 - $5.42 $771 - $1,712	316 Added 0.04%	790,936 $2.48 Million
Q3 2022 Nov 14, 2022	BUY	$4.95 - $6.6 $569,007 - $758,676	114,951 Added 17.01%	790,620 $3.96 Million
Q2 2022 Aug 12, 2022	BUY	$4.12 - $7.51 $1.88 Million - $3.43 Million	456,916 Added 208.87%	675,669 $3.82 Million
Q4 2021 Feb 14, 2022	SELL	$4.22 - $9.41 $5,384 - $12,007	-1,276 Reduced 0.58%	218,753 $954,000
Q2 2021 Aug 13, 2021	BUY	$6.91 - $12.59 $1.52 Million - $2.77 Million	220,029 New	220,029 $1.77 Million

Others Institutions Holding LYRA

# of Institutions

Shares Held

32.2M

Call Options Held

21.1K

Put Options Held

400

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $6.05M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Lyra Therapeutics, Inc. Transaction History